One Size Does Not Fit All: Using Population Pharmacokinetics (PK) for Tailored Hemophilia Care is organized by CME Outfitters, LLC.
Premiere Date: Tuesday, March 3, 2020
Credit Expiration Date: Wednesday, March 3, 2021
CME Credit (Physicians):
CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Statement of Need:
In order to prevent and treat bleeding in patients with hemophilia A, the activity of the replaced clotting factor VIII must reach or exceed a target level over a period of time. Pharmacokinetic (PK) measures are therefore used to determine the dosing regimen of the different factor VIII replacement products. Recently, extended half-life recombinant factor VIII products with improved PK profiles have been approved and these reduce treatment burden and improve treatment adherence.
In this CME Outfitters live and on-demand webcast, renowned hematologists will discuss the clinical significance of the results of the head-to-head comparison study of PK profiles of extended half-life factor VIII products including the application of population PK models and shared decision-making to provide personalized hemophilia A therapy.
At the end of this CE activity, participants should be able to:
• Summarize the comparative PK data and the clinical significance of popPK studies on factor VIII replacement therapies.
• Apply popPK models to determine individualized dosing regiments for patients with hemophilia A.
• Integrate approaches for SDM to develop patient-centered, PK-based treatment plans for patients with hemophilia A.
The following learning objectives pertain only to those requesting CNE or CPE credit:
• Explain popPK models that can determine individualized dosing regimens for patients with hemophilia A.
• Describe approaches for SDM to develop patient-centered, PK-based treatment plans for patients with hemophilia A.
Hematologists, physician assistants, nurse practitioners, nurses, and clinical pharmacists.